Related Experiment Video
Updated: Jun 26, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Effect of sirolimus on urinary bladder cancer T24 cell line
Rosario Pinto-Leite1, Pedro Botelho, Eufemia Ribeiro
1Genetic Service, Cytogenetic laboratory, Hospital center of Trás-os-Montes and Alto Douro, Vila Real, Portugal. mlleite@chtmad.min-saude.pt
Background:
Sirolimus is recently reported to have antitumour effects on a large variety of cancers. The present study was performed to investigate sirolimus's ability to inhibit growth in T24 bladder cancer cells.
Methods:
T24 bladder cancer cells were treated with various concentrations of sirolimus. MTT assay was used to evaluate the proliferation inhibitory effect on T24 cell line. The viability of T24 cell line was determined by Trypan blue exclusion analysis.
Results:
Sirolimus inhibits the growth of bladder carcinoma cells and decreases their viability. Significant correlations were found between cell proliferation and sirolimus concentration (r = 0.830; p < 0.01) as well as between cell viability and sirolimus concentration (r = -0.896; p < 0.01).
Conclusion:
Sirolimus has an anti-proliferation effect on the T24 bladder carcinoma cell line. The information from our results is useful for a better understanding sirolimus's anti-proliferative activity in the T24 bladder cancer cell line.
Insights
Sirolimus demonstrates significant anti-proliferative effects on T24 bladder cancer cells. This study confirms sirolimus
Area of Science:
- Oncology
- Pharmacology
Background:
- Sirolimus exhibits documented antitumor properties across diverse cancer types.
- The T24 bladder cancer cell line is a relevant model for studying bladder carcinoma.
Purpose of the Study:
- To investigate the efficacy of sirolimus in inhibiting the growth of T24 bladder cancer cells.
- To determine the dose-dependent effects of sirolimus on bladder cancer cell proliferation and viability.
Main Methods:
- T24 bladder cancer cells were exposed to varying concentrations of sirolimus.
- MTT assay was employed to assess the proliferation inhibitory effects.
- Trypan blue exclusion analysis was utilized to determine cell viability.
Main Results:
- Sirolimus significantly inhibited the growth of T24 bladder carcinoma cells.
- A strong positive correlation was observed between sirolimus concentration and growth inhibition (r = 0.830, p < 0.01).
- A strong negative correlation was found between sirolimus concentration and cell viability (r = -0.896, p < 0.01).
Conclusions:
- Sirolimus possesses a notable anti-proliferative effect on the T24 bladder carcinoma cell line.
- These findings enhance the understanding of sirolimus's mechanism in combating bladder cancer at the cellular level.
